Skip to main content
Explore URMC

menu

Prostate Cancer: ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS)

Research Question:
Is Darolutamide (ODM-201) effective at keeping your cancer under control when given in addition to standard treatment which includes androgen deprivation therapy (ADT) and docetaxel chemotherapy?

Basic Study Information

Purpose:
You will be randomly assigned to a treatment group, Darolutamide (ODM-201) or placebo. You will have a 1:1 chance of receiving Darolutamide (ODM-201) and a 1:1 chance of receiving placebo.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02799602?term=17777&rank=1
Study Reference #: IGUP16141

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Guancial

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351
Email: Ayesha_Khan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Prostate Cancer

Return to Search